Please assess the completion status of the following clinical trial:

Trial Title: A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females of non-childbearing potential.~* Established atherosclerotic cardiovascular disease (ASCVD) (criteria a) or ASCVD risk (criteria b):~  1. Age 40 years or older at the time of signing informed consent and history of ASCVD~ 2. Age above 50 years at the time of signing informed consent and with ASCVD risk~* Serum LDL-C above or equal to 1.8 mmol/L (above or equal to 70 mg/dL) as measured by the central laboratory at screening.~* Japanese participants: Serum LDL-C above or equal to 2.6 mmol/L (above or equal to 100 mg/dL) for participants of 40 years of age or older and with a history of coronary heart disease, and serum LDL-C above or equal to 3.1 mmol/L (above or equal to 120 mg/dL) for all other Japanese participants~* Participants must be on maximally tolerated dose of statins.~* Participants not receiving statin must have documented evidence of intolerance to all doses of at least two different statins.~Exclusion Criteria:~* Treatment with PCSK9i therapy (alirocumab or evolocumab within 90 days prior to screening) or PCSK9 siRNA therapy (inclisiran within 12 months prior to screening).~* Fasting triglyceride above 4.52 mmol/L (above 400 mg/dL) as measured by the central laboratory at screening.~* Myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within 180 days prior to the day of screening.~* Renal impairment with eGFR less than 30 ml/min/1.73 m2 as measured by the central laboratory at screening

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral NNC0385-0434 15 mg once-daily (OD) (Type: EXPERIMENTAL): 15 mg NNC0385-0434 co-formulated with 500 mg Salcaprozate sodium (SNAC) tablet once daily
- Oral placebo (NNC0385-0434 15 mg) (Type: PLACEBO_COMPARATOR): 15 MG placebo administered as tablets (without SNAC) once daily
- Oral NNC0385-0434 40 mg OD (Type: EXPERIMENTAL): 40 mg study drug co-formulated with 500 mg SNAC tablet once daily
- Oral placebo (NNC0385-0434 40 mg) (Type: PLACEBO_COMPARATOR): placebo administered as tablets (without SNAC) once daily
- Oral NNC0385-0434 100 mg (Type: EXPERIMENTAL): 100 mg NNC0385-0434 co-formulated with 500 mg SNAC tablet once daily (51 participants)
- Oral placebo (NNC0385-0434 100 mg) (Type: PLACEBO_COMPARATOR): placebo administered as tablets (without SNAC) once daily
- Subcutaneous evolocumab 140 mg Q2W (Type: ACTIVE_COMPARATOR): 140 mg evolocumab Subcutaneous (s.c.) injections every 2 weeks (51 participants). The s.c. evolocumab arm is open-label to limit unnecessary injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete